{
    "clinical_study": {
        "@rank": "144610", 
        "arm_group": {
            "arm_group_label": "Zelboraf Arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single-arm, multicenter study will assess the safety and efficacy of\n      Zelboraf (vemurafenib) in patients with Braf V600 mutation positive metastatic melanoma.\n      Patients will receive Zelboraf 960 mg twice a day until progressive disease, unacceptable\n      toxicity, consent withdrawal, death, reasons deemed by the treating physician or study\n      termination."
        }, 
        "brief_title": "An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults patients >= 18 years of age\n\n          -  Patients with histologically confirmed metastatic melanoma (surgically incurable and\n             unresectable stage IIIC or stage IV; AJCC) with documented BRAF V600 mutation\n             determined by the cobas\u00ae BRAF V600 Mutation Test prior to administration of\n             vemurafenib. Unresectable stage IIIC disease must have confirmation from a surgical\n             oncologist\n\n          -  Patients with either measurable or non-measurable disease (RECIST Version 1.1)\n\n          -  Patients may or may not have received prior systemic therapy for metastatic melanoma\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2\n\n          -  Patients must have recovered from all side effects of their most recent systemic or\n             local treatment for metastatic melanoma\n\n          -  Adequate hematological, renal, and liver function\n\n          -  Negative serum pregnancy test at screening\n\n          -  Fertile men and women must use an effective form of contraception during the study\n             and for at least 6 months after completion of the study\n\n        Exclusion Criteria:\n\n          -  Evidence of symptomatic CNS lesions as determined by the investigator, use of steroid\n             or anti-seizure medication for treatment of brain metastases prior to the first\n             administration of vemurafenib\n\n          -  Patients with previous malignancies (other than melanoma) within the past 2 years\n             except patients with treated and controlled basal or squamous cell carcinoma (SCC) of\n             the skin or carcinoma in-situ of the cervix.\n\n          -  Concurrent administration of any anti-cancer therapies (e.g. chemotherapy, other\n             targeted therapy, experimental drug, etc.) other than those administered in this\n             study\n\n          -  Known hypersensitivity to vemurafenib or another BRAF inhibitor\n\n          -  Pregnant or lactating women\n\n          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant\n             bowel resection that would preclude adequate absorption.\n\n          -  Any of the following within the 6 months prior to the first vemurafenib\n             administration: myocardial infarction, severe/unstable angina, symptomatic congestive\n             heart failure, cerebrovascular accident or transient ischaemic attack, pulmonary\n             embolism, hypertension not adequately controlled by current medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898585", 
            "org_study_id": "ML28711"
        }, 
        "intervention": {
            "arm_group_label": "Zelboraf Arm", 
            "description": "Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.", 
            "intervention_name": "Zelboraf", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bloemfontein", 
                        "country": "South Africa", 
                        "zip": "9301"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7700"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7570"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "George", 
                        "country": "South Africa", 
                        "zip": "6529"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groenkloof", 
                        "country": "South Africa", 
                        "zip": "0181"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2196"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa", 
                        "zip": "0002"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sandton", 
                        "country": "South Africa", 
                        "zip": "2196"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28711 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898585"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response rate according to Response evaluation criteria in solid tumors (RECIST v1.1)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}